Vir
is a California-based clinical-stage biotechnology company that researches and develops T-cell therapies for the treatment of infectious diseases... Read moreVir
is a California-based clinical-stage biotechnology company that researches and develops T-cell therapies for the treatment of infectious diseases... Read more
News
May 18, 2026
FinanzNachrichten
Vir: Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
May 18, 2026
Nasdaq
Vir: Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
May 16, 2026
Seeking Alpha
Vir: Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
May 11, 2026
Yahoo
Vir: Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 10, 2026
Yahoo
Vir: A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress
May 09, 2026
Nasdaq
Vir: Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
May 07, 2026
Owler
Vir Biotechnology, Inc.: Vir's revenue changed from $68.56M in Dec 2025 to $65.52M in Mar 2026
May 07, 2026
Seeking Alpha
Vir: Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028
May 06, 2026
Investing.com
Vir: Vir Biotech investors brace for earnings as losses shrink
Apr 16, 2026
Yahoo
Vir: Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Vir Competitors
1
2
3
4
5
6
7
8
9
10